Understand the source comparison
How to Boost Immune System with Peptides: Protocol Comparison
Thymosin Alpha-1 TLR9 activation → T-cell maturation, interferon-alpha production 1.6mg subcutaneous Twice weekly Phase 3 trials in hepatitis B/C showed 30–40% viral load reduction; 50–60% reduction in infection recurrence in immunocompromised patients Best ch
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR9 activation → T-cell maturation, interferon-alpha production
- 1.6mg subcutaneous
- Twice weekly
- Phase 3 trials in hepatitis B/C showed 30–40% viral load reduction; 50–60% reduction in infection recurrence in immunocompromised patients
- Best choice for systemic immune enhancement. Proven efficacy in multiple Phase 3 trials
- TB-500
- Actin polymerisation → accelerated immune cell migration to tissue damage
- 2–5mg subcutaneous
- Every 48–72 hours
- Wound healing studies showed 50% faster macrophage recruitment; reduced inflammatory cytokine release by 40%
- Primary use is tissue repair with secondary immune benefit. Not a direct immune activator
- LL-37
- Bacterial membrane disruption + neutrophil chemotaxis
- 1–2mg subcutaneous or topical
- Daily
- Reduced S. aureus colony counts by 90% in 24 hours in infected wounds; broad-spectrum antimicrobial activity
- Most effective for localised infections or wound care. Short half-life limits systemic immune benefit
- KPV
- NF-κB inhibition in gut epithelial cells → reduced inflammatory cytokine release
- 500mcg oral or 200–500mcg subcutaneous
- Three times daily (oral) or once daily (injectable)
- 40% reduction in colonic inflammation markers in ulcerative colitis patients
- Specialised use for gut-targeted immune modulation. Not systemic immune enhancement